Free Trial

Alto Neuroscience (ANRO) Stock Price, News & Analysis

Alto Neuroscience logo
$3.91 +0.32 (+8.83%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$3.90 -0.01 (-0.18%)
As of 08/22/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alto Neuroscience Stock (NYSE:ANRO)

Key Stats

Today's Range
$3.61
$3.93
50-Day Range
$2.21
$3.91
52-Week Range
$1.60
$15.04
Volume
157,542 shs
Average Volume
102,544 shs
Market Capitalization
$105.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

Alto Neuroscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

ANRO MarketRank™: 

Alto Neuroscience scored higher than 35% of companies evaluated by MarketBeat, and ranked 751st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alto Neuroscience has only been the subject of 1 research reports in the past 90 days.

  • Read more about Alto Neuroscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Alto Neuroscience are expected to grow in the coming year, from ($2.54) to ($2.39) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alto Neuroscience is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alto Neuroscience is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alto Neuroscience has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Alto Neuroscience's valuation and earnings.
  • Percentage of Shares Shorted

    10.00% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 4.88%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alto Neuroscience does not currently pay a dividend.

  • Dividend Growth

    Alto Neuroscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.00% of the float of Alto Neuroscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Alto Neuroscience has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Alto Neuroscience has recently increased by 4.88%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Alto Neuroscience has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 61 news articles for Alto Neuroscience this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for ANRO on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alto Neuroscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.13% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Alto Neuroscience's insider trading history.
Receive ANRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

ANRO Stock News Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.tc pixel
See More Headlines

ANRO Stock Analysis - Frequently Asked Questions

Alto Neuroscience's stock was trading at $4.23 at the beginning of the year. Since then, ANRO shares have decreased by 7.6% and is now trading at $3.9070.

Alto Neuroscience, Inc. (NYSE:ANRO) issued its earnings results on Wednesday, August, 13th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.08.

Alto Neuroscience (ANRO) raised $129 million in an IPO on Friday, February 2nd 2024. The company issued 8,040,000 shares at $16.00 per share.

Alto Neuroscience's top institutional investors include Armistice Capital LLC (6.00%), Marshall Wace LLP (3.46%), AWM Investment Company Inc. (1.04%) and Peapod Lane Capital LLC (1.03%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith.
View institutional ownership trends
.

Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/13/2025
Today
8/23/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ANRO
Previous Symbol
NYSE:ANRO
CIK
1999480
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$4.00
Potential Upside/Downside
+117.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.43 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-44.34%
Return on Assets
-36.73%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
18.43
Quick Ratio
18.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.56 per share
Price / Book
0.86

Miscellaneous

Outstanding Shares
27,080,000
Free Float
24,063,000
Market Cap
$105.80 million
Optionable
N/A
Beta
1.84

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NYSE:ANRO) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners